Omar Eton, MD

Associate Professor, Medical Oncology

Research Interest: Melanoma; Targeted Therapies; Clinical Trials

Selected Research Publications

Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm E, Bedikian AY. Pilot Study of High-Dose Concurrent Biochemotherapy for Advanced Melanoma. Cancer 101:596-603, 2004.

Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106:2005-11, 2006.

Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol. 33:280-5, 2006.

Hwang CS; Prieto VG; Diwan AH; Lizee G, Ellerhorst JA; Ekmekcioglu S; Liu P; Eton O; Kinney SA; Grimm EA; Hwu, P; Kim K.Changes in p-ERK1/2 and p-AKT Expression in Melanoma Lesions after Imatinib Treatment. Melanoma Res. 18:241-5, 2008.

Kim KB, Eton O, Davis D, McConkey D, Frazier M, Diwan AH, McGary E, Bar-Eli M, Ng C, Papadopoulos NE, Bedikian AY, Camacho LH, Billings L, Ross MI, Mansfield PF, Gershenwald J, Lee JE, Cormier J, Johnson MM, Murgo AM. Prieto VG. Phase II Trial of Imatinib Mesylate in Patients with Metastatic Melanoma. British J Cancer  99:734-40, 2008.

Kim, KB, Legha, SS, Gonzalez R, Anderson C, Papadopoulos NE, Eton O, Plager C, Roe A, Liu P, Bedikian AY. A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence. Melanoma Res. 19:42-9, 2009.

Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A, Halmos B, Favis R, Liu H, Trepicchio WL, Eton O, Shepherd FA.. Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer, J Thorac Oncol. 4:1002-9, 2009.

Eton O,  Savary CA,  Ross MI,  East MJ,  Mansfield PF, Papadopoulos N,  Plager C,  Bedikian AY, Reitsma D, Lee JE. Autologous tumor-derived heat-shock protein peptide complex-96 in patients with metastatic melanoma. J Transl Med. 8:9, 1-13, 2010.

Macarulla T, Cervantes A, Elez E, Rodriguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Molecular Cancer Therapeutics, Mol Cancer Ther. 9: 2844-52, 2010.

Dees EC, Infante JR,Cohen RB, O’Neil BH, Jones S, von Mehren M, Danaee H,4 Yih Lee Y, Ecsedy J,  Manfredi M,  Galvin K, Stringer B,  Liu H, Eton O, Fingert H, Burris H. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemotherapy & Pharmacology Cancer Chemother Pharmacol. 66: 1-10, 2010.

HONORS AND AWARDS

1975    Harvard Scholarship in recognition of academic achievement of the highest distinction

1988    American Cancer Society Clinical Oncology Fellowship

1995    Fellow of the American College of Physicians

1996    U.S. Meritorious Service Medal

Contact Details

Boston University Medical Center

820 Harrison Ave FGH-1 Room 1010

Boston MA 02118

617-638-2384 and 7520

omar.eton@bmc.org

Primary teaching affiliate
of BU School of Medicine